Vaccine and booster side effects can include fever, aches and fatigue. And this may be the first vaccine in history where people complain if they don't experience side effects, says one doctor.
In small studies in South Africa and in Germany, the results indicate a marked decrease in the ability of vaccines to neutralize this variant. But there are other findings that are encouraging.
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.
Pfizer researchers looking for a drug to treat SARS found clues that gave the company a head start in its quest for a pill to treat COVID-19, including the omicron variant.
Pfizer's CEO says the vaccine maker has asked federal regulators to authorize boosters for 16- and 17-year-olds. Currently, only people 18 and over are eligible for a booster in the U.S.
The FDA is considering new pills that could treat people in early stages of COVID. Here's what to know about how they work, how effective they are and the impact they could make on the pandemic.
The U.S. has pledged to deliver 1.1 billion doses of COVID vaccines to countries in need. Billions more are needed. NPR interviewed the State Department's global vaccine coordinator to learn more.
The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.
"With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19," the pharmaceutical giant said.
The challenge of refrigerating COVID-19 vaccines is acute in sub-Saharan Africa, where only 28% of health care facilities have reliable power. One solution? A new kind of freezer powered by the sun.
On the first European trip of his presidency, Biden will announce a major U.S. contribution to the global vaccine effort — part of an effort to end COVID-19 "everywhere."
The agreement provides a significant boost to the European Union's goal of getting 70% of adults vaccinated. Currently, around a quarter of the bloc's population is vaccinated.
One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."
Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them.
Many of the coronavirus vaccines like it cold. Really cold. Sub-zero cold. Why is this the case? And how is the world handling this frigid requirement?
Israel paid a premium, locked in an early supply of Pfizer-BioNTech vaccines and agreed to share data from Israel's centralized trove of medical statistics. Privacy advocates have some misgivings.
The two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind.
The new deal effectively doubles the federal government's order from the company. Pfizer says the U.S. government has agreed to pay $1.95 billion for the additional doses.
The top military official with the federal vaccine effort spoke less than 24 hours after Moderna's COVID-19 vaccine became the second to receive an emergency use authorization from the FDA.
Pfizer and BioNTech's vaccine is the first to receive an emergency authorization from the Food and Drug Administration. Officials say it may be ready for widespread inoculations within days.
